Carcinoma of liver and intrahepatic biliary tract

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:424936
Who is this for?
Show terms as
17Active trials18Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Carcinoma of the liver and intrahepatic biliary tract is a group of cancers that start in the liver itself or in the bile ducts located inside the liver. The two most common types are hepatocellular carcinoma (HCC), which begins in the main liver cells, and intrahepatic cholangiocarcinoma (iCCA), which starts in the small bile ducts inside the liver. Together, these cancers are sometimes called primary liver cancers, meaning they originate in the liver rather than spreading there from somewhere else in the body. The liver is a vital organ that filters the blood, helps digest food, and removes toxins from the body. When cancer develops in the liver, it can interfere with all of these functions. Many people do not notice symptoms in the early stages. As the disease progresses, symptoms such as abdominal pain, yellowing of the skin and eyes (jaundice), unexplained weight loss, and fatigue become more common. Treatment depends on how advanced the cancer is, the patient's overall health, and the specific type of cancer. Options include surgery to remove the tumor, liver transplantation, ablation therapies that destroy tumor cells, radiation, chemotherapy, and newer targeted therapies or immunotherapy drugs. Early detection greatly improves the chances of successful treatment, which is why regular monitoring is recommended for people at high risk.

Also known as:

Key symptoms:

Pain or discomfort in the upper right side of the abdomenYellowing of the skin and whites of the eyes (jaundice)Unexplained weight lossLoss of appetiteFeeling very tired or weakSwelling or bloating in the abdomenNausea or vomitingPale or chalky stoolsDark-colored urineItchy skinFever without a clear causeA hard lump felt under the ribs on the right side

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Mar 2026A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Mehmet Akce — PHASE2

TrialNOT YET RECRUITING
Oct 2025Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironment

Peking Union Medical College Hospital

TrialACTIVE NOT RECRUITING
Sep 2025A Study of GV20-0251 in Advanced or Refractory Solid Tumors

West China Hospital — PHASE1

TrialRECRUITING
Sep 2025cfDNA Methylation for Liver Cancer Recurrence Detection

Wuhan Ammunition Life-tech Co., Ltd

TrialRECRUITING
Aug 2025HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

Fudan University — PHASE2

TrialRECRUITING
Jan 2025Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer

Tianjin Medical University Cancer Institute and Hospital — PHASE2

TrialRECRUITING
Dec 2024Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data

Zhongda Hospital

TrialRECRUITING
Nov 2024Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver Resection

Warangkana Lapisatepun — NA

TrialRECRUITING
Oct 2024Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

HistoSonics, Inc.

TrialRECRUITING
Jun 2024A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

City of Hope Medical Center

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Carcinoma of liver and intrahepatic biliary tract.

17 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

17 recruitingView all trials with filters →
Phase 23 trials
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
Phase 2
Active
PI: David Hsieh (ECOG-ACRIN Cancer Research Group) · Sites: Auburn, California; Berkeley, California +35 more · Age: 1899 yrs
HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
Phase 2
Actively Recruiting
· Sites: Shanghai, Shanghai Municipality · Age: 1899 yrs
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
Phase 2
Actively Recruiting
· Sites: Tianjin · Age: 1875 yrs
Phase 13 trials
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Phase 1
Actively Recruiting
· Sites: Chengdu, Sichuan · Age: 1899 yrs
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
Phase 1
Active
PI: zhiping Yan, MD (Department of Interventional Radiology, Zhongshan ) · Sites: Shanghai, Shanghai Municipality · Age: 1880 yrs
Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer
Phase 1
Actively Recruiting
PI: Tingbo Liang (Zhejiang University) · Sites: Hangzhou, Zhejiang · Age: 1875 yrs
N/A2 trials
Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver Resection
N/A
Actively Recruiting
PI: Warangkana Lapisatepun, MD. PhD. (Chiang Mai University) · Sites: Chiang Mai, Chiangmai · Age: 2070 yrs
Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors
N/A
Active
PI: Director of Interventional Therapy Department (Fudan University) · Sites: Shanghai · Age: 1875 yrs
Other9 trials
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Active
PI: Binu John (Miami VA Healthcare System) · Sites: Chandler, Arizona; Sun City, Arizona +74 more · Age: 1899 yrs
Registry on Percutaneous Electrochemotherapy
Active
PI: Philipp Wiggermann, Prof. Dr. (Städtisches Klinikum Braunschweig, Braunschweig, G) · Sites: Montpellier; Paris +13 more · Age: 1899 yrs
Biobank for Cholestatic Liver Diseases.
Actively Recruiting
PI: Konstantinos Lazaridis, M.D. (Mayo Clinic) · Sites: Rochester, Minnesota · Age: 1885 yrs
cfDNA Methylation for Liver Cancer Recurrence Detection
Actively Recruiting
· Sites: Wuhan, Hubei · Age: 1899 yrs
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Actively Recruiting
· Sites: Fullerton, California; Mission Viejo, California +25 more · Age: 2299 yrs
Evaluation of Resection Techniques for Pancreatic Tumors
Actively Recruiting
PI: Alejandro Mejia, M.D. (The Liver Institute, Methodist Dallas Medical Cent) · Sites: Dallas, Texas · Age: 1899 yrs
Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironment
Active
· Sites: Beijing, Beijing Municipality · Age: 1880 yrs
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
Actively Recruiting
PI: Gao-Jun Teng, M.D (Zhongda hospital, Southeast university, Nanjing, C) · Sites: Nanjing, Jiangsu · Age: 1899 yrs
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Actively Recruiting
PI: Ajay Goel, PhD (City of Hope Medical Center) · Sites: Duarte, California · Age: 1899 yrs

Specialists

18 foundView all specialists →
TD
Thomas J. Ettrich, Dr.
Specialist
PI on 1 active trial
KM
Konstantinos Lazaridis, M.D.
ROCHESTER, MN
Specialist
PI on 1 active trial
NA
Nilofer S Azad
BALTIMORE, MD
Specialist
PI on 3 active trials1 Carcinoma of liver and intrahepatic biliary tract publication
JM
Jonathan M Hernandez, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 2 active trials
DH
David Hsieh
Specialist
PI on 1 active trial4 Carcinoma of liver and intrahepatic biliary tract publications
RS
Rachna T Shroff
TUCSON, AZ
Specialist
PI on 1 active trial13 Carcinoma of liver and intrahepatic biliary tract publications
AM
Anthony El-Khoueiry, MD
LOS ANGELES, CA
Specialist
PI on 2 active trials1 Carcinoma of liver and intrahepatic biliary tract publication
BJ
Binu John
RICHMOND, VA
Specialist
PI on 1 active trial11 Carcinoma of liver and intrahepatic biliary tract publications
GM
Gao-Jun Teng, M.D
Specialist
PI on 1 active trial
GP
Gabriel PERLEMUTER, MD, PhDi
Specialist
PI on 1 active trial
MM
Marc Engelhardt, MD
MANCHESTER, MO
Specialist
PI on 3 active trials
MM
Mehmet Akce, MD
BIRMINGHAM, AL
Specialist
PI on 2 active trials
EB
Emma Barrett
PHILADELPHIA, PA
Specialist
PI on 1 active trial1 Carcinoma of liver and intrahepatic biliary tract publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Carcinoma of liver and intrahepatic biliary tract.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Carcinoma of liver and intrahepatic biliary tractForum →

No community posts yet. Be the first to share your experience with Carcinoma of liver and intrahepatic biliary tract.

Start the conversation →

Latest news about Carcinoma of liver and intrahepatic biliary tract

Disease timeline:

New recruiting trial: Biobank for Cholestatic Liver Diseases.

A new clinical trial is recruiting patients for Carcinoma of liver and intrahepatic biliary tract

New recruiting trial: HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

A new clinical trial is recruiting patients for Carcinoma of liver and intrahepatic biliary tract

New recruiting trial: LEOPARD Training and Validation Data Collection Study

A new clinical trial is recruiting patients for Carcinoma of liver and intrahepatic biliary tract

New recruiting trial: Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data

A new clinical trial is recruiting patients for Carcinoma of liver and intrahepatic biliary tract

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What type and stage of liver cancer do I have, and what does that mean for my treatment options?,Should my tumor be tested for specific genetic mutations, and how will those results affect my treatment?,Am I a candidate for surgery, liver transplantation, or ablation therapy?,What clinical trials are available for my type and stage of cancer?,What are the most important side effects to watch for with the treatment you are recommending?,How will we monitor whether the treatment is working, and how often will I need scans or blood tests?,Should I or my family members be tested for any inherited conditions that may have contributed to this cancer?

Common questions about Carcinoma of liver and intrahepatic biliary tract

What is Carcinoma of liver and intrahepatic biliary tract?

Carcinoma of the liver and intrahepatic biliary tract is a group of cancers that start in the liver itself or in the bile ducts located inside the liver. The two most common types are hepatocellular carcinoma (HCC), which begins in the main liver cells, and intrahepatic cholangiocarcinoma (iCCA), which starts in the small bile ducts inside the liver. Together, these cancers are sometimes called primary liver cancers, meaning they originate in the liver rather than spreading there from somewhere else in the body. The liver is a vital organ that filters the blood, helps digest food, and removes

How is Carcinoma of liver and intrahepatic biliary tract inherited?

Carcinoma of liver and intrahepatic biliary tract follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Carcinoma of liver and intrahepatic biliary tract typically begin?

Typical onset of Carcinoma of liver and intrahepatic biliary tract is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Carcinoma of liver and intrahepatic biliary tract?

Yes — 17 recruiting clinical trials are currently listed for Carcinoma of liver and intrahepatic biliary tract on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Carcinoma of liver and intrahepatic biliary tract?

18 specialists and care centers treating Carcinoma of liver and intrahepatic biliary tract are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.